An Investigation of the relationship between adverse event and efficacy of treatment with lenvatinib in patients with unresectable hepatocellular carcinoma
Not Applicable
- Conditions
- advanced hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000034805
- Lead Sponsor
- Sapporo Medical University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1)Clinically significant ascites (i.e., refractory ascites requiring drainage) 2)History of liver transplantation 3)Esophageal varices with the potential to bleed 4)Concurrent or prior hepatic encephalopathy 5)Brain tumor 6)Currently on dialysis 7)Active double cancer 8)Orally taking an herbal medicine approved for the treatment of cancer (e.g., sho-saiko-to) 9)Human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS) -related disease 10)Pregnant or nursing 11)Otherwise found by the investigator or subinvestigator to be ineligible as a subject
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method efficacy
- Secondary Outcome Measures
Name Time Method